On Wednesday, 17 June 2026, 10X Genomics Inc (NASDAQ:TXG) reported that its shares increased by approximately 3.8% following the announcement of a multi‑year research collaboration with the Cleveland Clinic focused on bladder‑cancer biomarker discovery. The collaboration will leverage 10X’s single‑cell and spatial analysis platforms—including Flex Apex, Xenium and the newly announced Atera platform—to examine tumor samples from patients with advanced bladder cancer who are receiving emerging therapeutic regimens. Researchers intend to profile the tumor microenvironment, assess immune‑cell infiltration and measure expression of therapeutic targets, aiming to elucidate mechanisms of response and resistance to antibody‑drug conjugates and immunotherapies. Cleveland Clinic’s Timothy Chan, MD, PhD, Chair of the Department of Cancer Sciences, stated that the partnership has the potential to shed new light on therapeutic response mechanisms across major cancer types. The study will integrate single‑cell transcriptomic profiling, spatial gene‑expression analysis and protein measurements to create a comprehensive dataset that links cellular and spatial insights with clinical outcomes. 10X Genomics noted that the partnership aligns with its broader strategy to collaborate with research institutions to generate evidence supporting future diagnostic applications across oncology and other disease areas.